Quick Answer
Intellia Therapeutics, Inc. reported Total Revenue of $67.67 million for fiscal year 2025.
Intellia Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $67.67M +16.9% |
$57.88M +59.6% |
$36.27M -30.4% |
$52.12M +57.7% |
$33.05M -43.0% |
$57.99M +34.5% |
| Revenue (ASC 606) | $67.67M +16.9% |
$57.88M +59.6% |
$36.27M -30.4% |
$52.12M +57.7% |
$33.05M -43.0% |
$57.99M +34.5% |
| Net Income | -$412.69M +20.5% |
-$519.02M -7.9% |
-$481.19M -1.5% |
-$474.19M -77.0% |
-$267.89M -99.6% |
-$134.23M +71.7% |
| Diluted EPS | -$3.81 +27.4% |
-$5.25 +3.1% |
-$5.42 +12.0% |
-$6.16 -63.0% |
-$3.78 -57.5% |
-$2.40 |
| Total Assets | $842.13M -29.3% |
$1.19B -8.5% |
$1.30B -14.4% |
$1.52B +17.4% |
$1.29B +91.4% |
$676.32M +102.3% |
| Cash and Equivalents | $155.46M -17.8% |
$189.18M -16.6% |
$226.75M -56.7% |
$523.51M +324.2% |
$123.41M -22.9% |
$160.02M +179.6% |
| Stockholders Equity | $671.39M -23.0% |
$871.96M -17.0% |
$1.05B -15.0% |
$1.24B +18.8% |
$1.04B +97.4% |
$527.07M +95.3% |
| R&D Expense | $388.86M -16.6% |
$466.31M +7.2% |
$435.07M +3.6% |
$419.98M +82.8% |
$229.81M +52.8% |
$150.41M +38.7% |
| Operating Income | -$440.99M +17.5% |
-$534.26M -3.7% |
-$515.29M -12.5% |
-$458.16M -71.1% |
-$267.85M -96.1% |
-$136.58M -28.4% |
| Shares Outstanding | 116.32M +14.0% |
102.03M +9.7% |
93.00M +6.8% |
87.10M +16.9% |
74.49M +12.5% |
66.23M +31.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $13.78M | +51.3% | -3.3% |
| Revenue (ASC 606) | September 30, 2025 | $13.78M | +51.3% | -3.3% |
| Net Income | September 30, 2025 | -$101.32M | +25.3% | -0.1% |
| Diluted EPS | September 30, 2025 | -$0.92 | +31.3% | +6.1% |
| Total Assets | September 30, 2025 | $925.27M | -21.1% | +2.9% |
| Cash and Equivalents | September 30, 2025 | $193.39M | +60.5% | +23.8% |
| Stockholders Equity | September 30, 2025 | $748.42M | -22.3% | +4.6% |
| R&D Expense | September 30, 2025 | $94.75M | -23.2% | -2.4% |
| Operating Income | September 30, 2025 | -$111.48M | +23.0% | -1.3% |
| Shares Outstanding | September 30, 2025 | 115.79M | +13.7% | +9.9% |
- Intellia Therapeutics, Inc. reported Total Revenue of $67.67 million for fiscal year 2025.
- Intellia Therapeutics, Inc. showed an increase of +16.9% in Total Revenue compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported Revenue (ASC 606) of $67.67 million for fiscal year 2025.
- Intellia Therapeutics, Inc. showed an increase of +16.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported Net Income of -$412.69 million for fiscal year 2025.
- Intellia Therapeutics, Inc. showed an increase of +20.5% in Net Income compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported Diluted EPS of $3.81 per share (loss) for fiscal year 2025.
- Intellia Therapeutics, Inc. showed an increase of +27.4% in Diluted EPS compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported Total Assets of $842.13 million for fiscal year 2025.
- Intellia Therapeutics, Inc. showed a decrease of -29.3% in Total Assets compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported Cash and Equivalents of $155.46 million for fiscal year 2025.
- Intellia Therapeutics, Inc. showed a decrease of -17.8% in Cash and Equivalents compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported Stockholders Equity of $671.39 million for fiscal year 2025.
- Intellia Therapeutics, Inc. showed a decrease of -23.0% in Stockholders Equity compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported R&D Expense of $388.86 million for fiscal year 2025.
- Intellia Therapeutics, Inc. showed a decrease of -16.6% in R&D Expense compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported Operating Income of -$440.99 million for fiscal year 2025.
- Intellia Therapeutics, Inc. showed an increase of +17.5% in Operating Income compared to the prior fiscal year.
- Intellia Therapeutics, Inc. reported Shares Outstanding of 116.32 million shares for fiscal year 2025.
- Intellia Therapeutics, Inc. showed an increase of +14.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: